| Age |
704 |
65 (58, 71) |
61 (56, 67) |
<0.001 |
| Gender |
704 |
|
|
<0.001 |
| Female |
|
42 (10.0%) |
61 (22%) |
|
| Male |
|
379 (90%) |
222 (78%) |
|
| BMI |
704 |
27.5 (25.2, 30.5) |
27.7 (25.5, 31.5) |
0.2 |
| SmokingStatus |
704 |
|
|
0.056 |
| Current |
|
103 (24%) |
90 (32%) |
|
| Former |
|
134 (32%) |
91 (32%) |
|
| Never |
|
184 (44%) |
102 (36%) |
|
| Hypertension |
704 |
|
|
<0.001 |
| Hypertension |
|
232 (55%) |
119 (42%) |
|
| No hypertension |
|
189 (45%) |
164 (58%) |
|
| HighCholesterol |
699 |
|
|
0.6 |
| High cholesterol |
|
236 (56%) |
162 (58%) |
|
| Normal cholesterol |
|
185 (44%) |
116 (42%) |
|
| DiabetesMellitus |
704 |
|
|
0.13 |
| Diabetes Mellitus |
|
78 (19%) |
40 (14%) |
|
| No Diabetes Mellitus |
|
343 (81%) |
243 (86%) |
|
| IschaemicHeartDisease |
704 |
|
|
0.004 |
| Coronary artery disease |
|
98 (23%) |
41 (14%) |
|
| No coronary artery disease |
|
323 (77%) |
242 (86%) |
|
| MyocardialInfarction |
704 |
|
|
0.3 |
| Myocardial infarction |
|
66 (16%) |
36 (13%) |
|
| No previous myocardial infarction |
|
355 (84%) |
247 (87%) |
|
| PreviousPCI |
704 |
|
|
0.007 |
| No previous PCI |
|
349 (83%) |
255 (90%) |
|
| Previous PCI |
|
72 (17%) |
28 (9.9%) |
|
| PreviousCABG |
704 |
|
|
0.9 |
| No previous CABG |
|
402 (95%) |
271 (96%) |
|
| Previous CABG |
|
19 (4.5%) |
12 (4.2%) |
|
| PeripheralVascularDisease |
704 |
|
|
0.11 |
| No peripheral vascular disease |
|
412 (98%) |
271 (96%) |
|
| Peripheral vascular disease |
|
9 (2.1%) |
12 (4.2%) |
|
| StrokeTIA |
704 |
|
|
0.2 |
| Cerebrovascular disease |
|
23 (5.5%) |
10 (3.5%) |
|
| No cerebrovascualr disease |
|
398 (95%) |
273 (96%) |
|
| ECGFinding |
704 |
|
|
0.6 |
| NSTEMI |
|
147 (35%) |
94 (33%) |
|
| STEMI |
|
274 (65%) |
189 (67%) |
|
| SeverityCAD_4C |
704 |
|
|
0.6 |
| 1 Vessel |
|
16 (3.8%) |
12 (4.2%) |
|
| 2 Vessels |
|
224 (53%) |
163 (58%) |
|
| 3 Vessels |
|
149 (35%) |
90 (32%) |
|
| Left main stem disease |
|
32 (7.6%) |
18 (6.4%) |
|
| Aspirin |
673 |
|
|
|
| Aspirin use |
|
405 (100%) |
268 (100%) |
|
| P2Y12Antagonist |
688 |
|
|
|
| P2Y12 receptor antagonist use |
|
409 (100%) |
279 (100%) |
|
| Anticoagulant |
42 |
|
|
|
| Anticoagulant use |
|
25 (100%) |
17 (100%) |
|
| Statin |
653 |
|
|
|
| Statin use |
|
393 (100%) |
260 (100%) |
|
| ACEInhibitorOrARB |
623 |
|
|
|
| ACE inhibitor or ARB use |
|
373 (100%) |
250 (100%) |
|
| BetaBlocker |
573 |
|
|
|
| β-Adrenergic receptor antagonist use |
|
340 (100%) |
233 (100%) |
|
| CalciumChannelBlocker |
64 |
|
|
|
| Calcium-channel antagonist use |
|
45 (100%) |
19 (100%) |
|
| Nitrate |
384 |
|
|
|
| Nitrate use |
|
226 (100%) |
158 (100%) |
|
| OtherAntiAnginal |
22 |
|
|
|
| Other antianginal therapy use |
|
14 (100%) |
8 (100%) |
|
| Mineralocorticoid |
42 |
|
|
|
| Mineralocorticoid receptor antagonist use |
|
21 (100%) |
21 (100%) |
|
| OtherDiuretic |
54 |
|
|
|
| Other diuretic therapy use |
|
32 (100%) |
22 (100%) |
|